NCT00276276View on ClinicalTrials.gov

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

November 30, 2000

Conditions
Lung Cancer, Small Cell
Interventions
DRUG

topotecan

Trial Locations (17)

1115

GSK Investigational Site, Budapest

1145

GSK Investigational Site, Budapest

1529

GSK Investigational Site, Budapest

2045

GSK Investigational Site, Törökbálint

3529

GSK Investigational Site, Miskolc

4000

GSK Investigational Site, Plovdiv

8900

GSK Investigational Site, Hungary

9010

GSK Investigational Site, Varna

9300

GSK Investigational Site, Csorna

79031

GSK Investigational Site, Lviv

Unknown

GSK Investigational Site, Pleven

GSK Investigational Site, Donetsk

4819 EV

GSK Investigational Site, Breda

115 478

GSK Investigational Site, Moscow

CM1 7ET

GSK Investigational Site, Chelmsford

G21 3UW

GSK Investigational Site, Glasgow

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00276276 - Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter